Lomitapide, an FDA‐approved lipid‐lowering drug, has been shown to prevent tumor cell growth and enhance therapeutic efficacy in multiple myeloma and glioma.[24, 25] To confirm the interaction between lomitapide and RFWD3, we performed drug affinity responsive target stability (DARTS) and cell thermal shift assays (CETSA). This evidence concerns the gene RFWD3 and plasma cell myeloma.